Other substances

Infliximab

An anti-TNF-α antibody.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
21
 AI-suggested references
5
 Clinical trials

General information

Infliximab is a chimeric (human/murine) monoclonal antibody blocking tumour necrosis factor-alpha, which is a pro-inflammatory cytokine. Infliximab is used in the treatment of numerous inflammatory conditions including ulcerative colitis, rheumatoid arthritis, psoriasis, or Crohn’s disease (DrugBank).

Infliximab on Wikipedia

(Structure image from DrugBank)

Marketed as

AVSOLA; FLIXABI; INFLECTRA; OMVYENCE; REMICADE; REMSIMA; RENFLEXIS; ZESSLY

 

Structure image - Infliximab

Supporting references

Link Tested on Impact factor Notes Publication date
Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit
Severe severity Antibody Mixed substance Cohort study 		Intubated severe COVID-19 patients 1.00

Lower mortality was observed in patients treated with infliximab or infliximab combined with IVIg compared to control. The control group was statistically significantly older than the monotherapy group and numerically-only than the combined therapy group, however. Sample size: 27 + 11 (combined with IVIg) + 43 control. Dosage: A single 5 mg/kg infusion.


 Feb/01/2021

AI-suggested references

Link Publication date
Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies.
Aug/12/2020
Switch to infliximab subcutaneous during SARS-CoV-2 pandemic: preliminary results.
Sep/15/2021
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.
Sep/17/2021
Efficacy of switching from infliximab to golimumab in patients with ulcerative colitis in deep remission.
Mar/10/2021
Recent research on the application of biologics in the treatment of multisystem inflammatory syndrome in children after SARS-CoV-2 infection.
Feb/26/2022
TNF-alpha Blockers Showed Prophylactic Effects in Preventing COVID-19 in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthropathies: A Case-Control Study.
Jul/23/2021
SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis
Jan/29/2022
Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease
Sep/17/2021
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFalpha-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure.
Jun/25/2021
COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy versus apremilast in North Spain
Sep/30/2021
Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs
Jan/06/2021
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
Mar/16/2022
Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe Covid-19 pneumonia: a case report
Jan/15/2022
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients
Mar/09/2021
Pediatric Crohn's Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated with Infliximab
Mar/26/2021
Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: A case series
Jan/20/2022
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Apr/26/2021
Antiviral Activities of Halogenated Emodin Derivatives against Human Coronavirus NL63
Jun/21/2021
Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID-19) pandemic: A case series
Jun/27/2021
Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
Nov/18/2021
Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies
Apr/01/2022

Clinical trials

ID Title Status Phase Start date Completion date
NCT05220280 SOLIDARITY Finland Plus Long COVID-19 Not yet recruiting Phase 4 Feb/06/2022 Dec/01/2025
  • Alternative id - SOLP21
  • Interventions - Drug: Imatinib|Drug: Infliximab
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 400
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Long-COVID symptoms|Health-related quality of life|Mortality|Incidence of comorbidity|Lung function|Whole-genome sequencing
NCT04922827 Infliximab in the Treatment of Patients With Severe COVID-19 Disease Recruiting Phase 2 Jun/18/2021 Jul/01/2023
  • Alternative id - ZKSJ0137_INFLIXCOVID|2021-002098-25
  • Interventions - Drug: Infliximab|Other: Standard of Care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Jena University Hospital, Jena, Germany
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 88
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - 28-day mortality|safety of Infliximab administration|assessment of the effect of infliximab on an excessive immune response in patients with COVID-19: Interleukin 6|assessment of the effect of infliximab on an excessive immune response in patients with COVID-19: ferritin|assessment of the effect of infliximab on an excessive immune response in patients with COVID-19: lymphocyte count|assessment of the severity and frequency of organ failure: ventilation-free days|assessment of the severity and frequency of organ failure: renal replacement therapy-free days|assessment of the severity and frequency of organ failure: vasopressor-free days|occurence of Acute Respiratory Distress Syndrome (ARDS)|WHO-COVID-19-Progression Scale|rate of admission to the intensive care unit|length of stay: hospital|length of stay: intensive care unit|mortality|health related quality of life: visual analogue scale|health related quality of life: index|incidence of cardiomyopathy
NCT04593940 Immune Modulators for Treating COVID-19 Completed Phase 3 Oct/15/2020 Mar/05/2022
  • Alternative id - Pro00106301
  • Interventions - Drug: Infliximab|Drug: Abatacept|Drug: Remdesivir|Drug: cenicriviroc (closed to enrollment as of 3-Sep-2021)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Banner University Medical Center, Phoenix, Arizona, United States|University of Arkansas Medical Sciences, Little Rock, Arkansas, United States|Scripps Clinical Medical Group, La Jolla, California, United States|UCLA - Ronald Reagan Medical Center, Los Angeles, California, United States|Riverside University, Moreno Valley, California, United States|UC Irvine Medical Center, Orange, California, United States|Stanford University Medical Center, Palo Alto, California, United States|UCLA Medical Center- Santa Monica, Santa Monica, California, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|University of Florida-Jacksonville, Jacksonville, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Tulane School of Medicine, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Johns Hopkins Medical Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|U Mass Memorial Medical Center, Worcester, Massachusetts, United States|U Mass University Medical Center, Worcester, Massachusetts, United States|MidMichigan Medical Center- Gratiot, Alma, Michigan, United States|MidMichigan Medical Center - Midland, Midland, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Missouri Health Care, Columbia, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Trinitas Hospital, Elizabeth, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers New Jersey Medical School, New Brunswick, New Jersey, United States|NYU Brooklyn, Brooklyn, New York, United States|University at Buffalo, Buffalo, New York, United States|Flushing Hospital Medical Center, Flushing, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|NYU Long Island, Long Island City, New York, United States|New York University Langone Medical Center, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|St Lawrence Health System, Potsdam, New York, United States|University of Rochester Medical Center-Strong Memorial Hospital, Rochester, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Mercy Saint Vincent Medical Center, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Reading Hospital Study, Wyomissing, Pennsylvania, United States|Avera McKennan Hospital, Sioux Falls, South Dakota, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Methodist Health System Clinical Research Institute, Dallas, Texas, United States|University of Texas Health Science Center - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Trinity Mother Frances Hospital, Tyler, Texas, United States|University of Texas Health Center at Tyler, Tyler, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Providence Medical Research Center, Spokane, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Gundersen Health System, La Crosse, Wisconsin, United States|Hospital Interzonal Dr Jose Penna Bahia Blanca, Bahía Blanca, Buenos Aires, Argentina|Sanatorio Ramon Cereijo, Caba, Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Buenos Aires, Argentina|Clinica Central S.A., Villa Regina, Rio Negro, Argentina|Hospital Ramos Mejia, Buenos Aires, Argentina|Hospital Rawson, Cordoba, Argentina|Sanatorio Allende, Córdoba, Argentina|Sanatorio Britanico, Rosario, Argentina|Sanatorio Diagnóstico/ Instituto del Buen Aire, Santa Fe, Argentina|Hospital Brasília, Brasília, DF, Brazil|Hospital Felício Rocho, Belo Horizonte, MG, Brazil|Instituto DOR de Ensino e Pesquisa Hospital Glória D'Or, Rio De Janeiro, Rio De Janeiro / RJ, Brazil|Hospital Ernesto Dornelles, Porto Alegre, Rio Grande D Sul /RS, Brazil|Hospital de Clinicas de Porto Alegre HCPA, Porto Alegre, Rio Grande Do Sul / RS, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul/RS, Brazil|Hospital e Maternidade Celso Pierro - PUC Campinas, Campinas, São Paulo/SP, Brazil|Nuevo Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Guadalajara, Guadalajara Jalisco, Mexico|Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Nuevo León, Monterrey, Mexico|Hospital Central FAP, Lima, Lima/Lima, Peru|Hospital Regional Lambayeque, Chiclayo, Peru|Hospitala Nacional Hipólito Unánue, Lima, Peru|Hospital Nacional Aezobispo Loayza, Lima, Peru|Hospital de Chancay y Servicios Basicos de Salud, Lima, Peru|Clínica Belén SANNA, Piura, Peru
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 1971
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of patients that recovered from COVID-19|Change in number of patients hospitalized on invasive mechanical ventilation|number of patients that improved clinically|Number of patient deaths|Number of patients with decreased supplemental oxygenation needed|Change in number of patients needing non-invasive ventilation/ high flow oxygen|Number of days patients are in the hospital|Number of SAEs and AEs of grade 3 and 4|Number of patients with changes in abnormal WBC counts
NCT04425538 A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19). Completed Phase 2 Jun/01/2020 Jan/22/2021
  • Alternative id - STUDY00000564
  • Interventions - Drug: Infliximab
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Tufts Medical Center, Boston, Massachusetts, United States
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 17
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to Improvement in Oxygenation|Number of p[Atients With Improvement in Oxygenation|28-Day Survival Status|Duration of Supplemental Oxygen Administration by Nasal Cannula|Duration of Non-invasive Ventilation or by Non-rebreather Mask or High-flow Nasal Cannula|Number of Patients Requiring Mechanical Ventilation|Number of Patients Requiring Vasopressor Support|Number of Patients Requiring Extracorporeal Membrane Oxygenation|Number of Patients With Fever|Correlation of Cytokine Profile to Clinical Outcomes Specified in Primary and Secondary Objectives|Duration of Hospitalization|Number of Patients Who Developed Secondary Infections|Number of Patients Requiring Supplemental Oxygen Administration by Nasal Cannula|Duration of Mechanical Ventilation|Number of Patients Requiring Non-invasive Ventilation or by Non-rebreather Mask or High-flow Nasal Cannula|Assessment of Cytokine and Inflammatory Profile at Baseline and at 48 Hours After Therapy
NCT04734678 Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome Recruiting Dec/01/2020 Jun/01/2021
  • Alternative id - COVID-Infliximab
  • Interventions - Drug: Tocilizumab|Drug: Infliximab
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Teachers Hospital, Cairo, Please Select, Egypt
  • Study designs - Observational Model: Cohort|Time Perspective: Other
  • Enrollment - 84
  • Age - 18 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - Patients' clinical status improvement using six category scale|Time to improvement in oxygenation|Duration of hospitalization|Mortality rate|Incidence of non-invasive mechanical ventilation|Duration of non-invasive mechanical ventilation|Incidence of invasive mechanical ventilation|Duration of invasive mechanical ventilation|Occurrence of Secondary infections|Monitoring of adverse events|Occurrence of cardiovascular events
Export (.csv)